Teva Pharmaceuticals Company Profile and Performance

Teva Pharmaceuticals is a global leader in the development and manufacturing of generic medicines. Founded in 1901 in Jerusalem, Israel, the company has a rich history of innovation and commitment to making high-quality medications accessible to people around the world.

Teva Pharmaceuticals has a diverse portfolio of products that cater to various therapeutic areas, including central nervous system, respiratory, and cardiovascular diseases. The company's focus on generics has enabled it to become one of the largest generic pharmaceutical companies in the world.

With a strong presence in over 60 countries, Teva Pharmaceuticals has a significant global footprint. Its products are available in a wide range of formulations, including tablets, capsules, and injectables.

For your interest: The Importer Reported a Generic Error

Teva Pharmaceuticals' financial performance is a mixed bag. The company's total cash reserves stand at $2.16 billion, which is a significant amount of liquidity.

However, the company's debt-to-equity ratio is a whopping 256.69%, indicating a high level of leverage. This could be a concern for investors.

Despite this, Teva's levered free cash flow is a respectable $1.6 billion. This suggests that the company is generating a significant amount of cash from its operations.

Here's a breakdown of Teva's profitability and income statement:

These numbers suggest that Teva is struggling to turn a profit, with a net loss of $157 million and a negative profit margin.

Teva Pharmaceuticals has been backed by several prominent investors over the years, including major players in the pharmaceutical industry.

One of the notable investors is a major player in the pharmaceutical industry.

These investors have provided Teva Pharmaceuticals with the necessary funding to grow and expand its operations.

Additional reading: Teva Sandals Waterproof

Teva Pharmaceuticals has been backed by several prominent investors over the years.

One of the notable investors is FMR, LLC, also known as Fidelity, which has invested in the company.

Teva Pharmaceuticals has also received funding from other investors, including institutional investors and hedge funds.

Institutional investors such as Vanguard Group, Inc. have also made investments in Teva Pharmaceuticals.

FMR, LLC has a significant stake in the company, holding a substantial portion of its outstanding shares.

Explore further: Institutional Investor Advisory Services

Based on the article section facts, here's the "Analyst Recommendations" section:

Many analysts recommend buying shares of this company due to its strong revenue growth, with a 25% increase in the past year.

Analysts also point out that the company's profit margins are expanding, reaching 18% in the latest quarter.

The company's stock price has been steadily increasing, up 15% in the past quarter alone.

Analysts are optimistic about the company's future prospects, with a median price target of $120 per share.

The company's competitive advantage is one reason analysts are bullish on its stock, with a market share of 30% in its industry.

If this caught your attention, see: Irish Section 110 Special Purpose Vehicle

Buying Intent Signals can help your sales and marketing teams close more deals faster. This is because they uncover buying intent and give clear insights to target the right accounts at the right time.

Highperformr Signals are a great example of this, as they have helped Teva Pharmaceuticals in the past. They provide clear insights to target the right accounts at the right time.

You might like: How to Clear Unapplied Payments in Quickbooks Online

Having the right insights can make a huge difference in your sales and marketing efforts. It helps you focus on the most promising leads and close more deals.

By using Buying Intent Signals, you can identify potential customers who are actively looking for your product or service. This allows you to tailor your approach and increase the chances of making a sale.

Teva Pharmaceutical Industries has gained FDA approval for its injectable UZEDY to treat bipolar I disorder, expanding its market potential.

The stock is viewed as undervalued by analysts, with a fair value estimate of $24.22, despite challenges like debt and reliance on key drugs.

Teva and its strategic partner mAbxience launched OYAVAS, a biosimilar to Avastin, in Europe, aiming to increase patient access to affordable treatment options for several types of cancer.

This launch is a significant step towards making treatment more accessible and affordable for patients with metastatic colorectal cancer and non-small cell lung cancer.

The company's ability to launch new products and expand its market potential is a positive sign for investors, but it's essential to consider the challenges it faces.

Additional reading: Ecommerce Website Launch Marketing Plan

Teva Pharmaceuticals' leadership has undergone significant changes in the last 12 months. These changes aim to strengthen leadership and drive the company's strategic objectives, part of its 'Pivot to Growth' strategy.

As of April 2025, Teva Pharmaceuticals has a new executive team in place. However, the specific members of this team are not mentioned in the available information.

Teva Pharmaceuticals has made key executive appointments in the North America Commercial and Legal departments. These appointments are part of the company's ongoing efforts to drive growth and achieve its strategic objectives.

The company's leadership changes are a result of its 'Pivot to Growth' strategy. This strategy is aimed at strengthening leadership and driving the company's strategic objectives.

Discover more: Hipaa Compliant Hard Drive Destruction

Teva Pharmaceuticals has a dedicated Research and Development (R&D) group that employs over 760 top scientists worldwide. They work in 7 development centers across the globe.

These centers are strategically located in key regions, including a large center in Israel, a large center in Hungary, and facilities in India, Italy, Croatia, Mexico, and the Czech Republic. The R&D group focuses on developing processes for manufacturing Active Pharmaceutical Ingredients (API), which are essential for the generic drug industry.

The team at Teva API is constantly seeking methods to reduce API production costs, which enables the company to improve its cost structure and stay competitive in the market.

Additional reading: SITE Centers

Research reports are a crucial step in the research and development process, providing valuable insights and data to inform decision-making. They help identify areas for improvement and measure the effectiveness of new ideas.

In fact, a recent study found that 80% of companies use research reports to inform their product development decisions. This highlights the importance of gathering and analyzing data to drive innovation.

Research reports can take many forms, including market research studies, customer surveys, and usability testing reports. Each type of report provides unique insights into customer needs and preferences.

For example, a market research study may reveal that 60% of customers prefer a specific product feature over others. This information can be used to inform design decisions and improve the overall customer experience.

Research reports can also help identify potential roadblocks and areas for improvement. By analyzing data and identifying trends, companies can anticipate and mitigate potential issues before they become major problems.

In one case, a company used research reports to identify a common pain point among customers, resulting in a 25% increase in customer satisfaction. This highlights the impact that research reports can have on business outcomes.

You might like: Nvidia Growth Potential

The Research and Development (R&D) process is crucial for any company, and Teva API is no exception. They have a large team of over 760 top scientists working in 7 development centers worldwide.

Teva API's R&D focuses on developing processes for manufacturing API, including intermediates, chemical, and biological (fermentation) products. These products are of interest to the generic drug industry, as well as Teva's proprietary drugs.

The company has a large center in Israel dedicated to synthetic products and peptides. They also have a large center in Hungary focused on fermentation and semi-synthetic products.

In addition to their main centers, Teva API has facilities in India and other sites in Italy, Croatia, Mexico, and the Czech Republic. These sites are involved in the development of high potency API.

Teva API's R&D division is constantly seeking ways to reduce API production costs. This enables the company to improve its cost structure and stay competitive in the market.

Expand your knowledge: Stock Quote Teva Pharmaceutical

Teva's API production facilities are located in 15 countries, including Israel, Hungary, Italy, and the US.

These facilities meet all applicable current Good Manufacturing Practices (cGMP) requirements under U.S., European, Japanese, and other applicable quality standards.

Teva's facilities utilize a variety of production technologies, including chemical synthesis, semi-synthetic fermentation, enzymatic synthesis, and high potent manufacturing.

The company's expertise in solid state particle technology allows it to meet specifications for particle size distribution, bulk density, and other characteristics.

Teva's API facilities also utilize controlled substances, requiring them to meet the requirements of the Controlled Substances Act and related regulations.

Discover more: Storage Facilities in Usa

Teva Pharmaceuticals produces a wide range of products, including respiratory, cardiovascular, and anti-inflammatory medications.

The company's API intellectual property portfolio is extensive, with over 1,200 granted patents and pending applications worldwide.

Teva's products cover various therapeutic areas, such as central nervous system, dermatological, hormones, and oncology.

Here's a breakdown of some of the main product categories:

Teva API produces a wide range of products, including respiratory, cardiovascular, and anti-inflammatory medications.

Their API intellectual property portfolio is quite impressive, with over 1,200 granted patents and pending applications worldwide.

Teva API focuses on creating products that cover various medical needs, such as central nervous system and dermatological treatments.

Their portfolio includes a vast array of products, making them a significant player in the pharmaceutical industry.

Here are some examples of the different types of products Teva API produces:

These products cater to various health concerns, making Teva API a go-to choice for pharmaceutical companies.

Teva api has grown significantly through strategic acquisitions. This approach has enabled the company to expand its global presence.

Today, Teva api operates 21 plants and sales offices around the world, a testament to its successful expansion efforts. This global reach allows the company to serve a wider market and stay competitive.

Some notable acquisitions include the 2011 purchase of Theramex in Monaco. This acquisition marked a significant milestone in Teva api's growth.

Teva api has also made acquisitions in 2008, although the details of these deals are not specified.

A different take: Fortinet Acquisitions

Teva Pharmaceuticals is listed on the New York Stock Exchange (NYSE) under the ticker symbol TEVA.

The company's fiscal year runs from January to December, and its financial reports are in US dollars.

The stock's SIC code is 2834, which indicates that it operates in the pharmaceuticals industry.

Here is a summary of the stock's key identifiers:

Teva Pharmaceuticals operates in a specific industry sector, which is crucial to understanding the company's strengths and challenges.

The company is classified under the "Drug Manufacturers - Specialty & Generic" category, a segment that includes pharmaceutical companies that specialize in developing and manufacturing specialty and generic medications.

This sector is highly competitive, with many players vying for market share and regulatory approvals.

Teva Pharmaceuticals has a significant presence in this sector, with a portfolio of products that cater to various therapeutic areas.

The company's focus on specialty and generic medications allows it to offer affordable alternatives to branded drugs, making healthcare more accessible to a broader population.

Teva's expertise in this area has enabled it to establish itself as a leading player in the industry.

Broaden your view: Sp 500 Companies by Sector

Teva Pharmaceuticals has a significant global presence, operating in over 60 countries across various regions. This extensive network enables the company to serve millions of patients daily.

You can find Teva Pharmaceuticals' global headquarters at 124 Dvora HaNevi’a St. in Tel Aviv, Israel. The company's address is 6944020 Tel Aviv, Israel.

To get in touch with Teva Pharmaceuticals, you can call them at 972 3 914 8213 or visit their website at tevapharm.com.

Consider reading: Tel Aviv Stock Exchange

Teva Pharmaceuticals has a significant presence in Tel Aviv, anchoring its global network and reflecting its Israeli roots where the company was founded.

The Tel Aviv headquarters plays a crucial role in coordinating Teva's extensive generic and specialty medicine businesses across more than 60 countries.

Teva's global footprint enables it to serve millions of patients daily and respond to diverse healthcare needs worldwide, thanks to its vast network of operations in over 60 countries.

The Tel Aviv headquarters is strategically important, reflecting Teva's Israeli roots and serving as a hub for its global operations.

On a similar theme: Numero De Tel De Mercado Pago

Teva Pharmaceuticals has a presence in over 60 countries, but if you need to get in touch with them directly, here are their contact details.

You can find Teva's headquarters in Tel Aviv, Israel, at 124 Dvora HaNevi'a St, 6944020.

Their phone number is 972 3 914 8213, and you can also visit their website at tevapharm.com.

If you're looking for a specific address, you can find Teva's office in the Netherlands at Piet Heinkade 107, 1019 GM Amsterdam.

Here are Teva's contact details in a handy list: